Carla Falkson, MBChB, MMed, MD

Carla Falkson, MD, MBChB, MMed, discusses the use of the antibody-drug conjugate sacituzumab govitecan-hziy in hormone receptor–positive, HER2-negative breast cancer.

Carla Falkson, MBChB, MMed, MD, discusses opportunities for de-escalating therapy in patients with HER2-positive breast cancer. 

Carla Falkson, MBChB, MMed, MD, discusses the potential to de-escalate chemotherapy in HER2-positive breast cancer.